Chang-Le Chen, Sang Joon Son, Noah Schweitzer, Hecheng Jin, Jinghang Li, Linghai Wang, Shaolin Yang, Chang Hyung Hong, Hyun Woong Roh, Bumhee Park, Jin Wook Choi, Young-Sil An, Sang Woon Seo, Yong Hyuk Cho, Sunhwa Hong, You Jin Nam, Davneet S. Minhas, Charles M. Laymon, George D. Stetten, Dana L. Tudorascu, Howard J. Aizenstein, Minjie Wu, Mayo Clinic Study of Aging
{"title":"Periventricular diffusivity reflects APOE ε4–modulated amyloid accumulation and cognitive impairment in the Alzheimer's disease continuum","authors":"Chang-Le Chen, Sang Joon Son, Noah Schweitzer, Hecheng Jin, Jinghang Li, Linghai Wang, Shaolin Yang, Chang Hyung Hong, Hyun Woong Roh, Bumhee Park, Jin Wook Choi, Young-Sil An, Sang Woon Seo, Yong Hyuk Cho, Sunhwa Hong, You Jin Nam, Davneet S. Minhas, Charles M. Laymon, George D. Stetten, Dana L. Tudorascu, Howard J. Aizenstein, Minjie Wu, Mayo Clinic Study of Aging","doi":"10.1002/alz.70659","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Altered glymphatic-related fluid dynamics are increasingly recognized as a feature of Alzheimer's disease (AD). We generalized an established diffusion imaging framework to quantify periventricular diffusivity (PVeD), hypothesizing that fast diffusion signals in the periventricular region can reflect amyloid beta (Aβ) deposition across the AD continuum.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Participants from two multi-site cohorts (<i>n</i> = 440 and 414), comprising cognitively unimpaired individuals, those with mild cognitive impairment, and patients with AD, were included. We tested and validated the association of PVeD with Aβ burden and core AD characteristics.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Lower PVeD was extensively associated with greater Aβ burden, neurodegeneration, cognitive impairment, and clinical severity in the clinical cohort. Importantly, the relationship between PVeD and Aβ burden was significantly modulated by apolipoprotein E (<i>APOE</i>) ε4 status; <i>APOE</i> ε4 carriers exhibited a replicable stronger negative association. Baseline PVeD also predicted longitudinal cognitive decline.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>These findings suggest that periventricular diffusion signals reflect <i>APOE</i> ε4–modulated Aβ burden and cognitive decline in AD.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>An automated method for quantifying periventricular diffusivity (PVeD) is developed.</li>\n \n <li>Lower PVeD is associated with higher amyloid load only in a mild cognitive impairment–dominant cohort.</li>\n \n <li>Higher amyloid burden may mediate the link between lower PVeD and poorer cognitive outcomes in the clinical cohort.</li>\n \n <li>Apolipoprotein E ε4 carriers show a reproducibly stronger inverse PVeD—amyloid association than non-carriers.</li>\n \n <li>Baseline PVeD can predict longitudinal Mini-Mental State Examination decline in two independent cohorts.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12444947/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70659","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Altered glymphatic-related fluid dynamics are increasingly recognized as a feature of Alzheimer's disease (AD). We generalized an established diffusion imaging framework to quantify periventricular diffusivity (PVeD), hypothesizing that fast diffusion signals in the periventricular region can reflect amyloid beta (Aβ) deposition across the AD continuum.
METHODS
Participants from two multi-site cohorts (n = 440 and 414), comprising cognitively unimpaired individuals, those with mild cognitive impairment, and patients with AD, were included. We tested and validated the association of PVeD with Aβ burden and core AD characteristics.
RESULTS
Lower PVeD was extensively associated with greater Aβ burden, neurodegeneration, cognitive impairment, and clinical severity in the clinical cohort. Importantly, the relationship between PVeD and Aβ burden was significantly modulated by apolipoprotein E (APOE) ε4 status; APOE ε4 carriers exhibited a replicable stronger negative association. Baseline PVeD also predicted longitudinal cognitive decline.
DISCUSSION
These findings suggest that periventricular diffusion signals reflect APOE ε4–modulated Aβ burden and cognitive decline in AD.
Highlights
An automated method for quantifying periventricular diffusivity (PVeD) is developed.
Lower PVeD is associated with higher amyloid load only in a mild cognitive impairment–dominant cohort.
Higher amyloid burden may mediate the link between lower PVeD and poorer cognitive outcomes in the clinical cohort.
Apolipoprotein E ε4 carriers show a reproducibly stronger inverse PVeD—amyloid association than non-carriers.
Baseline PVeD can predict longitudinal Mini-Mental State Examination decline in two independent cohorts.
期刊介绍:
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.